Strs Ohio Grows Holdings in Insmed Incorporated (NASDAQ:INSM)

Strs Ohio increased its position in shares of Insmed Incorporated (NASDAQ:INSMGet Rating) by 650.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,500 shares of the biopharmaceutical company’s stock after purchasing an additional 3,900 shares during the quarter. Strs Ohio’s holdings in Insmed were worth $96,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Cetera Advisor Networks LLC boosted its stake in Insmed by 15.1% in the first quarter. Cetera Advisor Networks LLC now owns 11,405 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 1,500 shares during the last quarter. MetLife Investment Management LLC boosted its stake in Insmed by 57.0% in the first quarter. MetLife Investment Management LLC now owns 62,884 shares of the biopharmaceutical company’s stock valued at $1,478,000 after acquiring an additional 22,831 shares during the last quarter. Panagora Asset Management Inc. purchased a new position in Insmed in the first quarter valued at about $660,000. Rhumbline Advisers boosted its stake in Insmed by 4.7% in the first quarter. Rhumbline Advisers now owns 127,777 shares of the biopharmaceutical company’s stock valued at $3,003,000 after acquiring an additional 5,723 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Insmed by 52.6% in the first quarter. Dimensional Fund Advisors LP now owns 624,309 shares of the biopharmaceutical company’s stock valued at $14,670,000 after purchasing an additional 215,093 shares during the period. 92.83% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Insmed news, VP Michael Alexander Smith sold 1,836 shares of the business’s stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $17.93, for a total value of $32,919.48. Following the completion of the transaction, the vice president now owns 54,332 shares of the company’s stock, valued at approximately $974,172.76. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, VP Michael Alexander Smith sold 1,836 shares of the company’s stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $17.93, for a total value of $32,919.48. Following the completion of the sale, the vice president now owns 54,332 shares of the company’s stock, valued at approximately $974,172.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 7,008 shares of the company’s stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $19.80, for a total transaction of $138,758.40. Following the completion of the sale, the chief executive officer now directly owns 249,708 shares of the company’s stock, valued at approximately $4,944,218.40. The disclosure for this sale can be found here. Insiders sold a total of 46,601 shares of company stock valued at $875,661 in the last quarter. Corporate insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on INSM shares. Credit Suisse Group lowered their price target on shares of Insmed to $52.00 in a research report on Tuesday, November 1st. StockNews.com started coverage on shares of Insmed in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Barclays lowered their price target on shares of Insmed from $37.00 to $35.00 and set an “overweight” rating on the stock in a research report on Friday. Cantor Fitzgerald lowered their price target on shares of Insmed from $53.00 to $49.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 25th. Finally, Cowen decreased their target price on shares of Insmed from $56.00 to $53.00 and set an “outperform” rating on the stock in a report on Friday, October 21st. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.36.

Insmed Price Performance

INSM stock opened at $20.88 on Friday. The company has a debt-to-equity ratio of 18.24, a current ratio of 4.59 and a quick ratio of 4.11. Insmed Incorporated has a one year low of $16.41 and a one year high of $28.94. The stock has a market cap of $2.83 billion, a PE ratio of -5.74 and a beta of 1.49. The firm has a 50 day simple moving average of $19.14 and a two-hundred day simple moving average of $21.41.

Insmed (NASDAQ:INSMGet Rating) last released its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.20). Insmed had a negative return on equity of 319.03% and a negative net margin of 179.37%. The company had revenue of $67.73 million during the quarter, compared to analysts’ expectations of $68.02 million. On average, analysts predict that Insmed Incorporated will post -3.65 EPS for the current fiscal year.

Insmed Company Profile

(Get Rating)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSMGet Rating).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.